[1] Misawa S, Lee E, Schiffer CA, Liu Z, Testa JR. Association of the translocation (15; 17) with malignant proliferation of promyelocytes in acute leukemia and chronic myelogenous leukemia at blastic crisis. 1986;67(2):270-4. https://doi.org/10.1182/blood.V67.2.270.270.
[2] T Sravani PP, Tandon A, Uppin MS, Uppin SG, Narendra A, Gundeti Sadashivudu TR. Acute Promyelocytic Leukaemia: A Large case series from Southern India based on clinical, pathological, immunophenotypic, cytogenetic and molecular studies. National Journal of Laboratory Medicine. 2019;8(4):8-12. https://doi.org/10.7860/NJLM/2019/42483:2365.
[3] Weis K, Rambaud S, Lavau C, Jansen J, Carvalho T, Carmo-Fonseca M, et al. Retinoic acid regulates aberrant nuclear localization of PML-RARα in acute promyelocytic leukemia cells. Cell. 1994;76(2):345-56. https://doi.org/10.1016/0092-8674(94)90341-7.
[4] Sterrenberg L, Haak HL, Brommer EJ, Nieuwenhuizen W. Evidence of fibrinogen breakdown by leukocyte enzymes in a patient with acute promyelocytic leukemia. Haemostasis. 1985;15(2):126-33. https://doi.org/10.1159/000215133.
[5] RD B. Acute myeloid leukaemia with recurrent genetic abnormalities. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 2008:81-9.
[6] Akhtar K, Ahmad S, Sherwani RK. Acute promyelocytic leukemia, hypogranular variant: a rare presentation. Clinics and Practice. 2011;1(1):e11. https://doi.org/10.4081/cp.2011.e11.
[7] Nowak D, Stewart D, Koeffler HP. Differentiation therapy of leukemia: 3 decades of development. Blood, The Journal of the American Society of Hematology. 2009;113(16):3655-65.
https://doi.org/10.1182/blood-2009-01-198911.
